Processa Pharmaceuticals, Inc. Debt Conversion, Original Debt, Amount
Processa Pharmaceuticals, Inc. (PCSA) reported Debt Conversion, Original Debt, Amount of $1.94 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-20.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionOriginalDebtAmount1 · last filed 2017-11-20
- Processa Pharmaceuticals, Inc. debt conversion, original debt, amount for the quarter ending 2017-09-30 was $1.92M.
- Processa Pharmaceuticals, Inc. debt conversion, original debt, amount for the quarter ending 2017-06-30 was $10.71K, a 0.01% increase year-over-year.
- Processa Pharmaceuticals, Inc. debt conversion, original debt, amount for the quarter ending 2017-03-31 was $10.59K, a 1.10% decline year-over-year.
- Processa Pharmaceuticals, Inc. debt conversion, original debt, amount for the quarter ending 2016-06-30 was $10.71K.
- Processa Pharmaceuticals, Inc. debt conversion, original debt, amount for fiscal 2015 was $174.36K.
| Period end | Debt Conversion, Original Debt, Amount 3 month | Debt Conversion, Original Debt, Amount 6 month | Debt Conversion, Original Debt, Amount 9 month | Debt Conversion, Original Debt, Amount 12 month |
|---|---|---|---|---|
| 2017-09-30 | $1.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-20 | $1.93M derived: sum of 2 quarters · filed 2017-11-20 | $1.94M 10-Q · filed 2017-11-20 | |
| 2017-06-30 | $10.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-10-04 | $21.29K 10-Q · filed 2017-10-04 | ||
| 2017-03-31 | $10.59K 10-Q · filed 2017-10-04 | |||
| 2016-06-30 | $10.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-10-04 | $21.41K 10-Q · filed 2017-10-04 | ||
| 2016-03-31 | $10.71K 10-Q · filed 2017-10-04 | |||
| 2015-12-31 | $174.36K 10-K · filed 2017-09-25 | |||
| 2015-09-30 | $20.00K 10-Q · filed 2017-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |